Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice Curis Inc CRIS

Curis Nasdaq/NYSE Compliance Notice

Curis, Inc. received a delisting determination letter from Nasdaq on November 2, 2026, because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. Due to a previous 1-for-20 reverse stock split in July 2026 and an existing Panel Monitor, the company is not eligible for a standard compliance period and faces immediate delisting risk. The company intends to appeal the decision to a Nasdaq Hearings Panel to stay the delisting process.

Counterparty
Nasdaq
4:22 PM ET 8-K
M&A Deal Fox Corp FOXA

Fox Signs $10.4B M&A Deal with Roku, Inc.

Fox Corp completed its acquisition of Roku, Inc., merging it into a new division called FOX Digital Platforms. The transaction was funded in part by a $2.0 billion amended term loan and an $8.4 billion bridge credit facility. Roku stockholders received $95.30 in cash and 0.9799 shares of FOX Class A common stock per share, resulting in former Roku holders owning approximately 26% of the combined company.

Value
$10.4B
Counterparty
Roku, Inc.

“The closing of this acquisition advances the long-term strategy of FOX. Beginning today, our top priority for the combined company is to continue to relentlessly serve audiences and partners, while reinforcing the openness and choice that is the essence of the Roku platform. Our shared entrepreneurial passion and clear conviction toward building the future together with our new Roku colleagues gives us great confidence in the opportunities ahead of us.”

Lachlan K. Murdoch, Executive Chair and Chief Executive Officer of Fox Corporation

“We started Roku more than two decades ago to give people a better way to watch TV, and that mission doesn’t change today. What does change is our reach and resources: FOX has a deep respect for Roku’s culture and wholly shares our commitment to staying open to every content partner. Our teams will keep building and innovating as they always have, now with the support and capabilities of FOX behind us. I’m proud of what Roku’s employees have built, and I’m excited about what comes next.”

Anthony Wood, Roku founder
4:21 PM ET 8-K/A
M&A Deal HF Foods Group Inc. HFFG

HF Foods Group M&A Deal with Searay Foods Inc.

HF Foods Group Inc. filed an amendment to its previous 8-K to provide required audited financial statements and pro forma information following its acquisition of Searay Foods Inc. and Morgan Foods Inc. The filing also corrects a previously reported metric, clarifying that the acquired group's revenue compound annual growth rate from 2019-2024 was 6.6%, while the 15% figure originally cited referred to EBITDA growth. The acquisition was completed on August 31, 2026, for a base purchase price of CAD$47.9 million.

Counterparty
Searay Foods Inc.
4:19 PM ET 8-K
M&A Deal Roku, Inc ROKU

Roku M&A Deal with Fox Corporation

Roku, Inc. completed its previously announced merger with Fox Corporation, becoming a wholly owned subsidiary of FOX. As part of the transaction, Roku was merged into a subsidiary of FOX and renamed Roku, LLC. In connection with the closing, Roku terminated its existing credit agreement with Citibank, N.A.

Counterparty
Fox Corporation
4:19 PM ET 8-K
M&A Deal Churchill Capital Corp XI AGLT

Agility Robotics M&A Deal with Churchill Capital Corp XI

Agility Robotics, Inc. (Legacy Agility) completed its business combination with the SPAC Churchill Capital Corp XI (CCXI) on November 4, 2026. Following the merger, the combined company began trading on Nasdaq under the ticker 'AGLT'. In connection with the closing, CCXI shareholders redeemed approximately $261.8 million worth of shares.

Counterparty
Churchill Capital Corp XI
4:16 PM ET 8-K
Capital Raise Zenas BioPharma, Inc. ZBIO

Zenas BioPharma Capital Raise

Zenas BioPharma filed a new prospectus supplement to increase its at-the-market (ATM) offering program capacity by $200 million. This replaces a prior supplement under which the company had already sold approximately $153.2 million in common stock, leaving $46.8 million unsold from the previous authorization.

Counterparty
Jefferies LLC
4:11 PM ET 8-K
Capital Raise Local Bounti Corporation LOCL

Local Bounti Capital Raise

Stockholders approved the issuance of up to 12,563,309 shares of common stock upon the conversion of a convertible note and 1,000,000 shares underlying a warrant issued to U.S. Bounti, LLC. The vote satisfies NYSE compliance requirements for issuing more than 20% of the company's outstanding shares in connection with the August 2026 Purchase Agreement.

Counterparty
U.S. Bounti, LLC
4:09 PM ET 8-K
Capital Raise aTYR Pharma INC ATYR

aTYR Pharma Capital Raise

aTyr Pharma, Inc. filed a prospectus supplement to establish an at-the-market (ATM) offering program for the sale of up to $79,994,251 of its common stock. The sales will be conducted through Jefferies LLC as the sales agent under an existing Open Market Sale Agreement. This filing allows the company to raise equity capital from time to time at prevailing market prices.

Counterparty
Jefferies LLC
4:08 PM ET 8-K
Nasdaq/NYSE Compliance Notice Fifth Era Acquisition Corp I FERA

Fifth Era Acquisition Corp I Nasdaq/NYSE Compliance Notice

Fifth Era Acquisition Corp I received an extension from Nasdaq to regain compliance with the minimum 400 total holders requirement for continued listing on the Nasdaq Global Market. The company has until March 15, 2027, to demonstrate compliance or face potential delisting of its Class A ordinary shares, units, and rights.

Counterparty
Nasdaq
Term
through March 15, 2027
4:07 PM ET 8-K
M&A Deal StageWise Strategies Corp. TEGO

Teg Overseas Signs $101M M&A Deal with Dreams Island Limited Liability Company

TEG Overseas, Inc., through its subsidiary TEG SPV LLC, entered into a non-binding preliminary agreement to acquire the Alfraganus hotel complex in Tashkent, Uzbekistan, from Dreams Island LLC. The proposed deal includes a cash payment of approximately $1 million and the assumption of $100 million in bank debt related to the construction of the six-hotel complex. The transaction is expected to close by June 30, 2027, subject to definitive agreements and bank consents.

Value
$101M
Counterparty
Dreams Island Limited Liability Company
4:06 PM ET 8-K
M&A Deal Bowman Consulting Group Ltd. BWMN

Bowman Consulting Group Signs $1B M&A Deal with Bernhard Capital Partners

Bowman Consulting Group Ltd. completed its merger with affiliates of Bernhard Capital Partners, with Bowman becoming a privately held wholly owned subsidiary. The all-cash transaction is valued at approximately $1 billion, with shareholders receiving $43.00 per share. As a result of the closing, Bowman's common stock has ceased trading and will be delisted from Nasdaq.

Value
$1B
Counterparty
Bernhard Capital Partners
4:06 PM ET 8-K
Capital Raise Janus Living, Inc. JAN

Janus Living Capital Raise

Janus Living, Inc. closed a registered underwritten public offering of 30,187,500 shares of Class A-1 common stock. The offering included the full exercise of the underwriters' option to purchase an additional 3,937,500 shares. The company entered into an underwriting agreement with a syndicate led by BofA Securities, J.P. Morgan, Wells Fargo, and Goldman Sachs.

Counterparty
BofA Securities, Inc.
4:06 PM ET 8-K
M&A Deal Sino Green Land Corp. SGLA

Sino Green Land Signs $720K M&A Deal with Hi-Quality Productions Inc

Sino Green Land Corporation completed the acquisition of an 80% stake in Hi-Quality Productions Inc from seller Cheng You. The consideration for this 40% portion of the total deal consisted of $216,000 in cash and 840,000 shares of common stock valued at $0.60 per share, totaling $720,000.

Value
$720K
Counterparty
Hi-Quality Productions Inc
4:06 PM ET 8-K
Nasdaq/NYSE Compliance Notice Barfresh Food Group Inc. BRFH

Barfresh Food Group Nasdaq/NYSE Compliance Notice

Barfresh Food Group Inc. received a deficiency notice from Nasdaq on November 5, 2026, for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The company has until May 4, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least 10 consecutive business days. Additionally, the company is currently under a separate compliance period until February 1, 2027, to meet the $35 million minimum market value of listed securities requirement.

Counterparty
Nasdaq
Term
180 days
4:06 PM ET 8-K/A
M&A Deal Medalist Diversified, Inc. MDRR

Medalist Diversified M&A Deal with Pilot Point Property

Medalist Diversified, Inc. filed this amendment to provide required financial statements and pro forma information regarding its previously announced acquisition of the Pilot Point Property in Texas. The property consists of a 15,118 square foot automotive service building on approximately 1.65 acres. This filing serves as a status and financial update to the definitive acquisition reported on September 18, 2026.

Counterparty
Pilot Point Property
4:01 PM ET 8-K
Capital Raise North Haven Net REIT

North Haven Net REIT Capital Raise of $58.6M

North Haven Net REIT sold approximately 2.79 million common shares in a continuous private offering for aggregate consideration of $58.6 million. The sale included Class S, Class F-I, Class I, and Class E common shares and was conducted as an unregistered sale of equity securities under Regulation D.

Value
$58.6M
3:53 PM ET 8-K
Capital Raise EQT Exeter Real Estate Income Trust, Inc.

EQT Exeter Real Estate Income Trust Capital Raise of $920K

EQT Exeter Real Estate Income Trust, Inc. issued multiple classes of common stock in private placements to independent directors and accredited investors. The transactions included the issuance of Class E, Class A-I, and Class A-II shares for total proceeds of approximately $0.92 million, primarily through the company's distribution reinvestment plan.

Value
$920K
Counterparty
Accredited investors
3:17 PM ET 8-K
Clinical Trial Data Braveheart Bio, Inc. BRVE

Braveheart Bio Clinical Trial Data

Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy (oHCM). The results showed meaningful improvements in exercise capacity (pVO2) and patient-reported outcomes, with 79% of patients achieving a Valsalva LVOT gradient below 30 mmHg at Week 52.

Counterparty
Hengrui Pharma
Term
52 weeks
2:49 PM ET 8-K
Capital Raise Ares Real Estate Income Trust Inc. ZARE

Ares Real Estate Income Trust Capital Raise of $19.9M

Ares Real Estate Income Trust Inc. issued 2,396,247 shares of its Class S-PR and Class I-PR common stock in private placements exempt from registration under Regulation D. The transactions, which occurred on November 2, 2026, generated total gross proceeds of approximately $19.9 million, including activity from the company's distribution reinvestment plan.

Value
$19.9M
2:35 PM ET 8-K
Capital Raise Invesco Commercial Real Estate Finance Trust, Inc. INCREF

Invesco Commercial Real Estate Finance Trust Capital Raise of $40M

Invesco Commercial Real Estate Finance Trust, Inc. sold approximately 1.6 million shares of common stock across three classes (Class S-1, Class S, and Class I) for total aggregate consideration of approximately $40.0 million. The shares were sold at prices ranging from $24.8655 to $24.9801 per share, which were based on the company's net asset value per share as of September 30, 2026. The transactions were conducted as unregistered sales of equity securities exempt from registration under Section 4(a)(2) of the Securities Act.

Value
$40M
2:35 PM ET 8-K
M&A Deal Andersons, Inc. ANDE

Andersons Signs $915M M&A Deal with Harvestone Low Carbon Partners, LP

The Andersons, Inc. has entered into a definitive agreement to acquire Harvestone Low Carbon Partners (HLCP) for $915 million, expanding its ethanol production capacity by 40% to approximately 730 million gallons annually. The deal includes three production facilities in North Dakota and Indiana and adds established carbon capture and sequestration (CCS) capabilities to the company's renewables platform. The transaction is expected to close in late 2026 or early 2027 and be immediately accretive to earnings and cash flows.

Value
$915M
Counterparty
Harvestone Low Carbon Partners, LP

“Our Renewables strategy is centered on expanding our low-carbon production platform through disciplined investments and capturing the growing value of renewable fuels. We have been evaluating ethanol plant acquisition opportunities for several years, and HLCP is exactly what we have been looking for.”

Bill Krueger, President and Chief Executive Officer of The Andersons

“We believe The Andersons is the right home for HLCP. Our organizations share a strong commitment to our employees, our communities and the customers we serve, and we see a strong cultural fit between our teams.”

Jeff Zueger, CEO of HLCP
12:05 PM ET 8-K
Clinical Trial Data Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]lapemelanotide zapixetar (VMT01) for advanced melanoma at the SITC 2026 meeting. The data showed a 75% disease control rate at the 3.0 mCi dose level with no dose-limiting toxicities or treatment-related serious adverse events reported across 20 patients. The findings support further investigation of this targeted alpha therapy for heavily pretreated patients who have failed prior immunotherapies.

11:54 AM ET 8-K
Capital Raise Warburg Pincus Access Fund, L.P.

Warburg Pincus Access Fund Capital Raise of $10M

Warburg Pincus Access Fund, L.P. sold unregistered limited partnership units for aggregate consideration of approximately $10.0 million on October 1, 2026. The sale was part of the Fund's continuous private offering and included units sold to third-party investors and independent directors across Class B1, B3, and E units. The Fund also disclosed its Transactional NAV per unit for various classes as of September 30, 2026, to establish pricing for these transactions.

Value
$10M
11:10 AM ET 8-K
Capital Raise Nuveen Farmland REIT

Nuveen Farmland REIT Capital Raise of $2.2M

Nuveen Farmland REIT sold an aggregate of 108,848.03 common shares across multiple classes (Type A-I, A-II, S, I, and E) for total consideration of approximately $2.2 million. The transactions were conducted as part of the company's ongoing continuous private offering exempt from registration under Regulation D.

Value
$2.2M
8:41 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced interim six-month results from its PRECISE-BTN multicenter U.S. study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The data showed that 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction, with a median reduction of 72% and no serious adverse events reported. These results demonstrate the safety and efficacy of the company's nonthermal Nanosecond Pulsed Field Ablation (nsPFA) technology in a clinical setting.

8:23 AM ET 8-K
Capital Raise 60 Degrees Pharmaceuticals, Inc. SXTP

60 Degrees Pharmaceuticals Capital Raise of $526K

60 Degrees Pharmaceuticals entered into inducement agreements with warrant holders to exercise existing warrants for 584,492 shares at a reduced price of $0.90 per share. In exchange for the cash exercise, the company will issue new unregistered warrants for up to 1,168,984 shares. The company expects to receive gross proceeds of approximately $526,042 to be used for working capital and general corporate purposes.

Value
$526K
8:00 AM ET 8-K
M&A Deal Acrivon Therapeutics, Inc. ACRV

Acrivon Therapeutics M&A Deal with Aqilion AB

Acrivon Therapeutics has acquired a portfolio of immunology and inflammation (I&I) assets from Swedish biotech Aqilion AB, including the Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program. The deal establishes I&I as a new strategic pillar for Acrivon, which plans to apply its AP3 precision medicine platform to these assets for indications such as Eosinophilic esophagitis (EoE).

Counterparty
Aqilion AB
7:57 AM ET 8-K
M&A Deal Crown PropTech Acquisitions CPTKW

Crown PropTech Acquisitions M&A Deal with Mkango Rare Earths Limited

Crown PropTech Acquisitions announced that the SEC has declared effective the Form F-4 registration statement for its pending business combination with Mkango Rare Earths Limited. The company has commenced mailing the definitive proxy statement to shareholders for an extraordinary general meeting scheduled for November 25, 2026, to vote on the merger. Upon closing, the combined company is expected to list on Nasdaq under the ticker MKAR.

Counterparty
Mkango Rare Earths Limited
7:01 AM ET 8-K
Clinical Trial Data Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced incremental Phase 1/2a clinical trial data for [212Pb]VMT-α-NET in patients with advanced neuroendocrine tumors (NETs). The data, presented at the NANETS 2026 Symposium, showed a 75% progression-free survival rate at 18 months and a 47% response rate in Cohort 3, supporting plans for a Phase 3 study initiation in 2027.

7:01 AM ET 8-K
Capital Raise Precision Biosciences Inc DTIL

Precision Biosciences Capital Raise of $125M

Precision BioSciences priced an underwritten public offering of approximately 10.2 million shares and 5.9 million pre-funded warrants for gross proceeds of $125 million. The offering included participation from several life sciences investors including First Light Asset Management and MPM BioImpact. Proceeds will fund research and development for PBGENE-HBV and PBGENE-DMD programs.

Value
$125M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.